Kakehasi, Adriana Maria http://orcid.org/0000-0001-9411-7493
Radominski, SebastiĆ£o Cezar
Baravalle, Marcos Daniel
Palazuelos, Fedra Consuelo Irazoque
Garcia-Garcia, Conrado
Arruda, Maysa Silva
Curi, Marco
Liu, John
Qiao, Meihua
Velez-Sanchez, Patricia
Vargas, Juan Ignacio
Funding for this research was provided by:
AbbVie
Article History
Received: 18 May 2022
Revised: 20 December 2022
Accepted: 10 January 2023
First Online: 30 January 2023
Declarations
:
: AMK has received personal consulting and/or speaking fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. SCR has received grants for clinical studies from AbbVie, Bristol-Myers Squibb, and Lilly and speaker fees from AbbVie, Amgen, Janssen, Pfizer, and UCB. MDB has received medical fees as a Clinical Investigator from AbbVie, Galapagos, and GlaxoSmithKline. FCIP has received speaker fees from AbbVie, Pfizer, Bristol-Myers Squibb, and Janssen; consulting fees from AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, and Pfizer; and medical fees as a Principal Investigator from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Pfizer, and Roche. CGG has received medical fees as a Principal Investigator from AbbVie. MSA, MC, JL, and MQ are employees of AbbVie and may own stock or options. PVS has received medical fees as a Principal Investigator from AbbVie. JIV has received medical fees as a Principal Investigator from AbbVie.
: All studies were conducted according to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines, applicable regulations and guidelines governing clinical study conduct, and the Declaration of Helsinki. Study-related documents were reviewed and approved by independent ethics committees and institutional review boards. All patients provided written informed consent before participation in the study.